The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
What is the optimal prognostic threshold for MFC MRD positivity in patients with AML?
Featured:
Roland WalterDuring the 2024 Transplantation & Cellular Therapy Meetings of ASTCT and CIMBTR, the AML Hub was pleased to speak with Roland Walter, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, What is the optimal prognostic threshold for multiparameter flow cytometric (MFC) minimal residual disease (MRD) positivity in patients with acute myeloid leukemia (AML)?
What is the optimal prognostic threshold for MFC MRD positivity in patients with AML?
Walter starts by highlighting the importance of MFC in detecting MRD in AML, which predicts worse outcomes in patients who are MRD positive compared with those who are MRD negative.
He then shares insights from his research in collaboration with GIMEMA, HOVON, and MRC/NCRI, looking at the potential for suboptimal discrimination of relapse risk with the current European LeukemiaNet MRD Working Group MRD cut-off of ≥0.1%. Walter emphasizes that a ‘one-size-fits-all’ approach may not be ideal for accurately assessing relapse risks and suggests that centralized MRD testing can help to establish optimal thresholds for prospective trials.
